Happel David — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Happel David has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $663K.

Profile

David Happel is the President and CEO of Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing selective fatty acid synthase inhibitors. He has held the role of Director and has been involved in the company's efforts to address diseases related to lipid metabolism dysfunction.

Board memberships

• Sagimet Biosciences Inc.

Awards & honors

• Leadership in biopharmaceutical development
• Development of denifanstat for NASH treatment

Recent Transactions

Companies — Last 90 Days

• Sagimet Biosciences Inc. (SGMT) — 1 filings, last 2026-06-02

Frequently Asked Questions

Who is Happel David?

David Happel is the President and CEO of Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing selective fatty acid synthase inhibitors. He has held the role of Director and has been involved in the company's efforts to address diseases related to lipid metabolism dysfunction.…

How many SEC Form 4 filings has Happel David submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has Happel David been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 2 open-market sales ($663K) across all tracked filings.

Where can I see all of Happel David's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week